Mr. Sebastian Gabriel De La Calle, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: Brian D. Allgood Army Community Hospital, Usag-humphreys, Bldg # 3030, Unit 15245, Apo, AP 96271 Phone: 315-737-2836 |
Dr. Alex Heaton Gubler, AUD Audiologist Medicare: Not Enrolled in Medicare Practice Location: Paf 374 Op Med Readiness Sq Ffgfz0, Apo, AP 96328 Phone: 813-325-9822 |
Laura Stephenson, AU.D. Audiologist Medicare: Not Enrolled in Medicare Practice Location: Psc 561 Box 1877, Fpo, AP 96310 Phone: 310-253-3104 |
Dr. Stefnie Glazer, AU.D., CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: Psc 475 Box 1, Fpo, AP 96350 Phone: 046-816-2624 |
Dr. Antony R Joseph, AUD, PHD Audiologist Medicare: Not Enrolled in Medicare Practice Location: Psc 482 Box 1600, Dch Audiology Clinic, Fpo, AP 96362 Phone: 011-816-117437806 Fax: 011-816-117437811 |
Dr. Matthew Zachary Thomas, AU.D Audiologist Medicare: Not Enrolled in Medicare Practice Location: Psc 475 Box 1889, Fpo, AP 96350 Phone: 315-243-2600 |
Dr. Michael Kiyoto Miyamura Audiologist Medicare: Not Enrolled in Medicare Practice Location: Psc 475 Box 1, Fpo, AP 96350 Phone: 315-243-8713 |
News Archive
In an article by Egan et al, titled, "Cyclooxygenases, Thromboxane, and Atherosclerosis," published in the Jan 17 issue of Circulation: Journal of the American Heart Association researchers examined some of the molecular mechanisms of drugs affecting prostaglandin and thromboxane production.
"Scientists are warning officials negotiating a global treaty on mercury that banning the deadly chemical completely would be dangerous for public health because of the chemical's use in vaccines," the Associated Press reports.
Medivation, Inc. and Astellas Pharma Inc. today announced that patient enrollment was completed on November 15, 2010 in the Phase 3 AFFIRM study of the investigational drug MDV3100, a novel, triple-acting oral androgen receptor antagonist, in patients with advanced prostate cancer who have previously been treated with chemotherapy. The companies also announced that clinical development of MDV3100 in Japan has commenced, with the initiation of patient dosing in a Phase 1-2 clinical study.
With rates and deaths associated with Clostridium difficile (C. difficile) at historically high levels, many hospitals have taken extra steps to reduce these infections. New research finds that a dedicated daily cleaning crew who adequately clean and disinfect rooms contaminated by C. difficile using a standardized process can be more effective than other disinfection interventions.
› Verified 5 days ago